MEIS2 suppresses breast cancer development by downregulating IL10
Cancer Reports · 2024
DOI: 10.1002/cnr2.2064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Yongzhi Xiao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound Diagnosis, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Homeodomain Proteins, Cell Proliferation, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Health Research Project of Hunan Provincial Health Commission.
Abstract (Originalsprache)
Background
Breast cancer (BC) is the most commonly diagnosed female cancer. Homeobox protein MEIS2, a key transcription factor, is involved in the regulation of many developmental and cellular processes. However, the role of MEIS2 in the development of breast cancer is still unclear.
Aims
We aimed to examine the role of myeloid ecotropic insertion site (MEIS2) in breast cancer and the association of MEIS2 with breast cancer clinical stages and pathological grades. We revealed the underlying mechanism by which MEIS2 affected breast cancer cell growth and tumor development. Methods and Results Using human BC cell lines, clinical samples and animal xenograft model, we reveal that MEIS2 functions as a tumor suppressor in breast cancer. The expression of MEIS2 is inversely correlated with BC clinical stages and pathological grades. MEIS2 knockdown (MEIS2‐KD) promotes while MEIS2 overexpression suppresses breast cancer cell proliferation and tumor development in vitro and in animal xenograft models, respectively. To determine the biological function of MEIS2, we screen the expression of a group of MEIS2 potential targeting genes in stable‐established cell lines. Results show that the knockdown of MEIS2 in breast cancer cells up‐regulates the IL10 expression, but MEIS2 overexpression opposed the effect on IL10 expression. Furthermore, the suppressive role of MEIS2 in breast cancer cell proliferation is associated with the IL10 expression and myeloid cells infiltration.
Conclusion
Our study demonstrates that the tumor suppressor of MEIS2 in breast cancer progression is partially via down regulating the expression of IL10 and promoting myeloid cells infiltration. Targeting MEIS2 would be a potentially therapeutic avenue for BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound Diagnosis, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Xiangya International Medical Center, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Oncology, Xiangya Hospital, Central South University, Hunan, China.
- The Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, China.
ORCID-Profile: Shangwei Zhong
Förderung
- The Health Research Project of Hunan Provincial Health Commission
Zitieren
APA
Xiao, Y., Liu, Y., Sun, Y., Huang, C., & Zhong, S. (2024). MEIS2 suppresses breast cancer development by downregulating IL10. Cancer Reports. https://doi.org/10.1002/cnr2.2064
Vancouver
Xiao Y, Liu Y, Sun Y, Huang C, Zhong S. MEIS2 suppresses breast cancer development by downregulating IL10. Cancer Reports. 2024. doi:10.1002/cnr2.2064
BibTeX
@article{Xiao2024,
author = {Xiao, Yongzhi and Liu, Yingzhe and Sun, Yangqing and Huang, Changhao and Zhong, Shangwei},
title = {MEIS2 suppresses breast cancer development by downregulating IL10},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.2064}
}
EUVIMED